ARTA
BLPH

A.R.T. Advisors’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

A.R.T. Advisors’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,032
Closed -$24K – 1779
2018
Q4 		$24K Buy
2,032
+720
+55% +$10.5K ﹤0.01% 1246
2018
Q3 		$21K Buy
+1,312
New +$31.2K ﹤0.01% 1345
2017
Q3 		– Sell
-1,560
Closed -$31K – 1837
2017
Q2 		$31K Buy
+1,560
New +$32.3K ﹤0.01% 1329
2016
Q1 		– Sell
-1,061
Closed -$47K – 1782
2015
Q4 		$47K Buy
+1,061
New +$51.4K ﹤0.01% 1385

Other funds holding BLPH

NMVA
New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return
PCM
Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

A.R.T. Advisors's BLPH Position: Q1 2019 in Review

A.R.T. Advisors sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q1 2019, closing a stake of 2,032 shares — an estimated $24K sold.

A.R.T. Advisors first reported a position in BLPH in Q4 2015 and held it in 4 quarters. The position peaked at $47K in Q4 2015. 26 funds tracked by Wall St. Rank hold BLPH as of Q1 2019.

  • A.R.T. Advisors reported no remaining Bellerophon Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 2,032 Bellerophon Therapeutics, Inc. shares in Q1 2019, an estimated $24K.
  • A.R.T. Advisors first reported a position in Bellerophon Therapeutics, Inc. in Q4 2015 and held it in 4 quarters.
  • A.R.T. Advisors's Bellerophon Therapeutics, Inc. position peaked at $47K in Q4 2015.
  • 26 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q1 2019.

Based on A.R.T. Advisors's 13F filing for Q1 2019, filed 15 May 2019.